Exclusive Online Content
Adare Pharma Solutions Acquires Frontida BioPharm to Expand Leading CDMO Offerings
Adare Pharma Solutions recently announced the acquisition of Frontida BioPharm, a vertically integrated CDMO focused on oral formulations. The acquisition reinforces….
Sterling Pharma Solutions Announces Exclusive Partnership to Develop Novel Route to Newly Approved COVID-19 Therapy
Sterling Pharma Solutions recently announced an exclusive partnership with the University of Manchester Institute of Biotechnology (MIB), to support the development of a novel, low-cost manufacturing route to molnupiravir, a new….
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected With Influenza Virus
SAB Biotherapeutics recently announced that SAB-176, its investigational therapeutic for the treatment of seasonal influenza, achieved statistically significant (p = 0.026) reductions in viral load and….
BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated With Schizophrenia & Bipolar Disorders
BioXcel Therapeutics, Inc. recently announced the US FDA has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application (NDA) of BXCL501 for the acute treatment of….
Akoya Biosciences Secures CLIA Lab Certification, a Milestone for Applying its Spatial Biology Technologies to Accelerating Precision Cancer Therapies
Akoya Biosciences, Inc., The Spatial Biology Company, recently announced its Advanced Biopharma Solutions (ABS) laboratory, located in Marlborough, MA, has received its Certificate of Registration from the….
Gb Sciences Accelerates Drug Development Via Innovative Biopharma Technology & Strategic Partnerships
Recognizing the glacial pace of traditional drug research and development processes and the adverse effect of this on patients, biopharmaceutical company Gb Sciences has taken innovative steps to speed up….
Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation
Revive Therapeutics Ltd. recently announced it has filed an application with the US FDA to receive Orphan Drug Designation (ODD) for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver….
Diffusion Pharmaceuticals Doses First Participants in Altitude Trial
Diffusion Pharmaceuticals Inc. recently announced it has dosed the first participants in its Altitude Trial. The trial will evaluate the company’s lead product candidate, trans sodium crocetinate (TSC)….
Decibel Therapeutics Announces Extension of Research Term Under Strategic Collaboration With Regeneron to Discover & Develop Gene Therapies for Hearing Loss
Decibel Therapeutics recently announced that Regeneron has extended the research term of its collaboration with the company to discover and develop gene therapies for hearing loss…..
Cytovia & Cellectis Expand Their TALEN Gene-Edited iNK Partnership to Enable Broader Collaboration in China
Cytovia Therapeutics, Inc. and Cellectis recently announced they have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells to include new CAR target and….
ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing & Manufacturing Next-Generation COVID-19 Vaccines
ImmunityBio, Inc. recently announced the expansion of the company’s cancer and infectious disease vaccine programs to include self-amplifying self-adjuvating RNA (SASA-RNA), recombinant protein vaccine candidates, and potent adjuvant formulations that….
Artizan Biosciences & Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease
Artizan Biosciences, Inc. and Biohaven Therapeutics Ltd. recently announced the companies are initiating a therapeutic discovery and development program in Parkinson’s disease (PD), to exploit recent….
Sever Pharma Solutions Acquires Foster Delivery Science
Sever Pharma Solutions (SPS) recently announced it has entered into a definitive agreement to acquire the assets of Foster Delivery Science (FDS) located in Putnam, CT…..
Arranta Bio Announces Completion of Sale of Florida Site & Progress on $150-Million Investment Plan to Expand Development & Commercial Manufacturing Services
Arranta Bio recently announced the completion of the sale of its process development and GMP clinical manufacturing site in Gainesville, FL, to Inceptor Bio and the transfer of client programs and key….
SOTIO Expands Its Antibody-Drug Conjugate Pipeline With Exclusive Collaboration & License Agreement With LegoChem Biosciences
SOTIO Biotech recently announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc in which SOTIO will obtain rights to deploy LCB’s ADC technology for up to….
Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline With a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) & Other Rare Ocular Surface Diseases
Kala Pharmaceuticals, Inc. recently announced it has acquired Combangio, Inc., a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases…..
Harpoon Therapeutics Presents Data on its TriTAC-XR Platform
Harpoon Therapeutics, Inc. recently presented a poster with preclinical data on its TriTAC-XR T cell engager platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, DC…..
Baxter Announced $100-Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility
Baxter International Inc. recently announced an approximately $100-million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany. This facility is….
Mustang Bio Announces Exclusive Worldwide License Agreement With Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy With Curative Potential for RAG1 Severe Combined Immunodeficiency
Mustang Bio, Inc. recently announced that the company has executed an exclusive license agreement with Leiden University Medical Centre (LUMC) for a first-in-class ex vivo lentiviral gene therapy for the….
First Own Gerresheimer Autoinjector - Gerresheimer & Midas Pharma Announce Strategic Partnership
Gerresheimer recently announced it has acquired the IP of a new generation cartridge-based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector…
